OBJECTIVE: The objective of this study is to compare the effectiveness and safety in the labor induction between the high dose oxytocin method and the new low dose oxytocin method. STUDY DESIGN: Firstly, we selected 125 pregnant women hospitalized, having the indication of labor induction from March, 1995 to August, 1996. Of them, we selected 61 pregnant women tothem the high dose oxytocin method was used, as the control group, and in- creased the quantity of 2.5 mU/min every 20 minutes with the start dose of 2.5 mU/min to them. On the other hand, with the start dose of 1.25 mU/min, we increased the quantity of 1.25 mU/min every 20 minutes to the study group of low dose oxytocin method, 64 pregnant women. RESULTS: No statistical significance was found in the time from the effective uterine contraction to the delivery in the study group, in contrast to that of the control group to them the labor induction was conducted by using the high dose oxytocin. Maximum amount used to the high dose oxytocin was significantly more than that of the low dose oxytacin, but in the total given dose, there was no significant difference between two groups. Maxi- mum uterine contraction of the control group did not show any significant. difference from that of the study group, and there was also no significant difference in the frequency of generating the complications such as fetal distress. CONCLUSION: There was no difference in the labor.induction -to delivery time, and the complications of fetus, between the existing high dose oxytocin method and the new low dose oxytocin method. Therefore it is thought the low dose oxytocin method may reduce the possibility of a complieation compared with the high dose oxytocin method. However, it is considered this matter must be investigated further in the futrre.
Female ; Fetal Distress ; Fetus ; Hand ; Humans ; Oxytocin* ; Pregnant Women ; Uterine Contraction

No abstract available.
Pregnancy*

No abstract available.
Chlamydia trachomatis* ; Chlamydia* ; Female ; Humans ; Infant, Newborn* ; Nasal Cavity* ; Polymers* ; Pregnancy ; Pregnancy Trimester, Third* ; Pregnancy*

BACKGROUND: Although post-anesthetic shivering may be a temporary phenomenon, it leads to detrimental effects such as increased oxygen consumption, hypoxemia, and difficulty in monitoring. Doxapram is a relatively new treatment for post-anesthetic shivering, but there have been few reports about its minimum effective dose. The purpose of this study was to find the minimum dose of doxapram which would show an antishivering effect. METHODS: Sixty patients who had developed post-anesthetic shivering were divided into six groups of ten patients each. The groups were divided into a control group, which received normal saline, and the doxapram groups, which received five different doses of doxapram (0.15, 0.2, 0.5, 1.0, 1.5 mg/kg). The antishivering effect (2, 5, 10, 15 minutes after treatment), blood pressure, heart rate and temperature were compared among the groups. RESULTS: There was a significant difference in antishivering effect between the group which received normal saline and the groups which received doxapram; however, there was no significant difference within the groups which received doxapram. CONCLUSIONS: We conclude that the dose of doxapram required to achieve an antishivering effect is much less than that currently in use.
Anoxia ; Blood Pressure ; Doxapram* ; Heart Rate ; Humans ; Oxygen Consumption ; Shivering*

BACKGROUND: Though the proper administration of midazolam in the geriatric patients under the spinal anethesia reduce the stress, the anxiety and the agitation during surgery, it can cause the hypoxemia owing to decreasing their ventilatory function, and the aim of this study was to evaluate the dose response of midazolam to determine the degree of hypoxemia, the change of cardiovascular functions after the intravenous administration of midazolam in geriatric patients during the period of TURP under the spinal anesthesia. METHODS: On thirty two geriatric male patients(> or =65 yrs), the changes of O2 saturation in pulse oximetry, systolic and diastolic pressure in NIBP, heart rate in EKG before and after the administration of midazolam were studied during perioperative period of TURP under the spinal anesthesia in randomized method, and they were allocated randomly to four groups to receive only normal saline (group 1), midazolam 0.01 mg/kg(group 2), midazolam 0.02 mg/kg(group 3), midazolam 0.03 mg/kg (group 4) in normal saline 3ml, respectively. RESULTS: The results were that the desaturation between 85% and 90% in SpO2 occurred in three patients(one patient in group 3, two patients in group 4), that the desaturation below 85% in SpO2 occurred in three patients (group 4), immediately 100% oxygen was administered to the patients by mask, that the occurrances of the desaturation below 90% in SpO2 appeared about 4-7minutes after the administration of midazolam and there was no statistically significant changes in cardiovascular function in all groups. CONCLUSIONS: It is concluded that the intravenous administration of midazolam more than 0.02 mg/kg can cause hypoxemia in geriatric patients under the spinal anesthesia and the close observation and monitoring must be needed during sedative period.
Administration, Intravenous ; Age Factors ; Anesthesia, Spinal* ; Anoxia ; Anxiety ; Blood Pressure ; Dihydroergotamine ; Electrocardiography ; Heart Rate ; Humans ; Hypnotics and Sedatives ; Male ; Masks ; Midazolam* ; Oximetry ; Oxygen ; Oxyhemoglobins* ; Perioperative Period ; Transurethral Resection of Prostate

Embryonal carcinoma, a very rare ovarian germ cell tumor, involves pure and mixed phenotypes. Pure-type embryonal carcinoma has never been reported in postmenopausal women. The current case was, thus, misdiagnosed as an epithelial ovarian carcinoma based on radiologic findings. Herein, we describe the case of ovarian embryonal carcinoma in a 75-year-old woman along with a literature review. Magnetic resonance imaging findings were suggestive of epithelial ovarian malignancy associated with endometrioma, including ureteral invasion. The patient underwent complete surgical staging, and a pathologic diagnosis of pure-type embryonal carcinoma was made. The patient’s postoperative course was uneventful, and adjuvant chemotherapy was administered. Embryonal carcinoma in the postmenopausal woman is a clinical challenge owing to the possibility of its misdiagnosis as epithelial ovarian carcinoma. To the best of our knowledge, this is the first report of pure-type ovarian embryonal carcinoma in a postmenopausal woman, with a description of the clinicopathologic characteristics and review of the relevant literature.

PURPOSE: Although upper airway cough syndrome (UACS) is one of the most common causes of chronic cough, there are few reports on the effects of intranasal steroids (INS) on improvement of cough in patients with chronic cough caused by UACS. Here, we observed improvement in cough depending on prescribed medications, including INS, in patients with chronic cough caused exclusively by UACS in the clinical setting. METHODS: Patients with chronic cough caused exclusively by UACS were selected by the retrospective review of medical records. Durations and kinds of prescribed medications, nasal and postnasal drip symptoms, and results of paranasal sinus series at first visit were evaluated. According to the improvement of cough at the second visit, the patients were divided into the improved and unimproved groups. Odds ratios of each medication in the improved group were analyzed by logistic regression adjusted for age, sex, smoking history, duration of treatment, prescriptions of medications, presence of nasal and postnasal drip symptoms, and results of paranasal sinus series. RESULTS: A total of 122 patients with chronic cough caused exclusively by UACS were comprised of 38 patients in the improved group and 84 patients in the unimproved group. INS were prescribed to 45 patients, and the number of patients with INS prescription were significantly higher in the unimproved group than that in not-improved group (55.3% vs. 28.6%, P=0.008). The odds ratio of INS prescription was significantly higher in the improved group (odds ratio, 4.78; 95% confidence interval, 1.03-22.3; P=0.046). CONCLUSION: INS could improve cough symptom in patients with UACS. These results warrant further evaluation.
Administration, Intranasal ; Cough* ; Humans ; Logistic Models ; Medical Records ; Odds Ratio ; Prescriptions ; Retrospective Studies ; Sinusitis ; Smoke ; Smoking ; Steroids*

No abstract available.
Aneurysm, Dissecting/diagnosis/*etiology/physiopathology/therapy ; Anticoagulants/therapeutic use ; Aortic Aneurysm/diagnosis/*etiology/physiopathology/therapy ; Behcet Syndrome/*complications/diagnosis/drug therapy ; Cerebral Infarction/diagnosis/etiology ; Diffusion Magnetic Resonance Imaging ; Echocardiography, Doppler, Color ; Electrocardiography ; Hemodynamics ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; *Sinus of Valsalva/physiopathology/ultrasonography ; Thrombosis/diagnosis/drug therapy/*etiology/physiopathology ; Ventricular Septal Rupture/diagnosis/*etiology/physiopathology/therapy

Background: The associations between thyroid cancer and skeletal outcomes have not been thoroughly investigated. We aimed to investigate the risk of osteoporotic fractures in patients with thyroid cancer compared to that in a matched control group. Methods: This retrospective cohort study included 2,514 patients with thyroid cancer and 75,420 matched controls from the Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC, 2006–2019). The rates of osteoporotic fractures were analyzed, and associations with the levothyroxine dose were evaluated. Results: Patients with thyroid cancer had a significantly lower risk of fracture than did the control group (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.69 to 0.94; P=0.006). Patients diagnosed with thyroid cancer after the age of 50 years (older cancer group) had a significantly lower risk of fracture than did those in the control group (HR, 0.72; 95% CI, 0.6 to 0.85; P<0.001), especially those diagnosed with spinal fractures (HR, 0.66; 95% CI, 0.51 to 0.85; P=0.001). Patients in the older cancer group started osteoporosis treatment earlier than did those in the control group (65.5±7.5 years vs. 67.3±7.6 years, P<0.001). Additionally, a lower dose of levothyroxine was associated with a reduced risk of fractures. Conclusion In the clinical setting, the risk of fracture in women diagnosed with thyroid cancer after the age of 50 years was lower than that in the control group, which was caused by more proactive osteoporosis treatment in postmenopausal women with thyroid cancer.

Background: The associations between thyroid cancer and skeletal outcomes have not been thoroughly investigated. We aimed to investigate the risk of osteoporotic fractures in patients with thyroid cancer compared to that in a matched control group. Methods: This retrospective cohort study included 2,514 patients with thyroid cancer and 75,420 matched controls from the Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC, 2006–2019). The rates of osteoporotic fractures were analyzed, and associations with the levothyroxine dose were evaluated. Results: Patients with thyroid cancer had a significantly lower risk of fracture than did the control group (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.69 to 0.94; P=0.006). Patients diagnosed with thyroid cancer after the age of 50 years (older cancer group) had a significantly lower risk of fracture than did those in the control group (HR, 0.72; 95% CI, 0.6 to 0.85; P<0.001), especially those diagnosed with spinal fractures (HR, 0.66; 95% CI, 0.51 to 0.85; P=0.001). Patients in the older cancer group started osteoporosis treatment earlier than did those in the control group (65.5±7.5 years vs. 67.3±7.6 years, P<0.001). Additionally, a lower dose of levothyroxine was associated with a reduced risk of fractures. Conclusion In the clinical setting, the risk of fracture in women diagnosed with thyroid cancer after the age of 50 years was lower than that in the control group, which was caused by more proactive osteoporosis treatment in postmenopausal women with thyroid cancer.